COVID-19 Genomics UK Consortium

Last updated

COVID-19 Genomics UK
New COG-UK logo.jpg
EstablishedApril 2020
Focus COVID-19 genomic sequencing
Key people Sharon Peacock
Budget£32.2 million [1]
Location
United Kingdom

The COVID-19 Genomics UK (COG-UK) consortium was a group of academic institutions and public health agencies in the United Kingdom created in April 2020 [1] [2] [3] to collect, sequence and analyse genomes of SARS-CoV-2 at scale, as part of COVID-19 pandemic response.

Contents

The genome data generated by COG-UK was integrated with epidemiological data and patient health records to monitor introductions into the UK, community transmission and outbreaks of SARS-CoV-2; to assess changes in transmissibility and virulence; and to evaluate the impact of treatments and non-pharmaceutical interventions. COG-UK members also undertook research that integrated human genomic and health data to understand the biology of SARS-CoV-2 and its impact on those infected. [4]

The consortium identified the SARS-CoV-2 Alpha variant (at the time, referred to as Variant of Concern 202012/01) in November 2020, which became the subject of subsequent investigations by the UK public health agencies, coordinated by Public Health England and supported by COG-UK. [5] [6]

Between April and September 2021, SARS-CoV-2 sequencing transitioned to become a public health-led national service, [7] after which COG-UK focused on data linkage, research and international training. [8]

The consortium formally closed at the end of March 2023. [4]

Funding

COG-UK was supported by £20 million funding from the Department of Health and Social Care, UK Research and Innovation (UKRI), and the Wellcome Sanger Institute. [1]

The consortium received a further £12.2 million from the Department of Health and Social Care's Testing Innovation Fund in November 2020 to facilitate the genome sequencing capacity needed to meet the increasing number of COVID-19 cases in the UK over the 2020–2021 winter period. [9]

Together with Wellcome Connecting Science, COG-UK was also awarded a Foreign, Commonwealth & Development Office/Wellcome Epidemic Preparedness Coronavirus grant of nearly £1 million to develop COG-Train, [10] a learning programme to support the global scientific and public health community in SARS-CoV-2 genome sequencing. [11]

Structure

The consortium comprised the four UK public health agencies, the Wellcome Sanger Institute, sixteen academic partners, and National Health Service organisations. It adopted a Hub and Spoke model with a centralised administrative hub (University of Cambridge), a national sequencing hub (Sanger Institute), and sequencing and analysis capacity regionally distributed across all partners. [12]

Samples from COVID-19 patients were collected by NHS laboratories, public health laboratories and national coronavirus testing centres and sent to partner sites for sequencing. Viral genome sequencing was undertaken by the four UK public health agencies, the Wellcome Sanger Institute, the Quadram Institute, and fifteen universities including Queen's University Belfast, the University of Birmingham, Cardiff University, the University of Cambridge, the University of Edinburgh, the University of Exeter, the University of Glasgow, the University of Liverpool, Northumbria University, the University of Nottingham, the University of Oxford, the University of Portsmouth, University College London, Imperial College London and the University of Sheffield. [13]

The rapid launch and delivery of SARS-CoV-2 genome sequencing data was enabled by use of the pre-existing infrastructure and expertise of COG-UK partners and members. For example, COG-UK relied on the Cloud Infrastructure for Microbial Bioinformatics (CLIMB), [14] which was launched in 2014 with support from the Medical Research Council. CLIMB is an open, cloud-based computing infrastructure for developing and sharing datasets and bioinformatics software, tools and methods to interpret ‘big data’. [15] CLIMB is a partnership between the Universities of Bath, Birmingham, Cardiff, Leicester, Swansea and Warwick, the London School of Hygiene and Tropical Medicine and the Quadram Institute. [16]

Genome data for each positive sample sequenced was linked to the person who provided the sample using an anonymous code. These were uploaded to CLIMB-COVID where the genomes could be characterised, which included assigning each genome to a lineage and detecting mutations. Public health agencies were then able to access this information and link it to detailed public health information. [17]

Key people

The executive director and chair of the consortium was Sharon Peacock, a professor and microbiologist at the University of Cambridge. [18] [19]

More than 600 consortium members contributed to the work of COG-UK between April 2020 and the end of March 2023, [20] with key roles fulfilled by researchers from across the consortium partners, [21] and a management team based at the University of Cambridge. [22]

Impact

COG-UK pioneered early and large-scale coordinated national sequencing of SARS-CoV-2 viral genomes, along with the open and rapid sharing of genomic data.

By December 2020, COG-UK had sequenced the genomes of more than 150,000 samples of SARS-CoV-2 virus and uploaded them to GISAID, representing around 5% of all UK COVID-19 cases. Approximately 60% of these were sequenced at the Wellcome Sanger Institute. By December 2021, the UK had sequenced over 1.8 million SARS-CoV-2 genomes.

The insights arising from analysis of these genome data had a range of impacts during the COVID-19 pandemic response: [23]

  1. Enabling the identification and monitoring of "Variants of Concern" and "Variants under Investigation" to inform public health actions and policy decisions. [19]
  2. Tracking the introduction and spread of COVID-19 to inform border control, outbreak management and public health policies. [24]
  3. Facilitating key UK COVID-19 studies:
    • The COG-UK HOCI (Hospital-Onset COVID-19 Infections) study [25] [26] [27]
    • The Office of National Statistics (ONS) COVID-19 Infection Survey (CIS) [28] [29]
    • The Real-time Assessment of Community Transmission (REACT) Study [30] [31]
    • The Vivaldi study [32] [33]
    • The Oxford Vaccine trial [34]
    • The Novavax Vaccine trial [35]
  4. Furthering understanding of the biology and evolution of the SARS-CoV-2 virus to guide treatments, vaccine development and diagnostics. [36]
  5. Boosting the pandemic response through rapid release of genome data and the development of efficient and cost-effective sequencing protocols and open-access public data analysis tools. [17]

By September 2021, COG-UK pivoted to focus on three strategic areas: [8]

  1. Enhancing the value of viral genome sequence data through more extensive data linkage, including human genome data and clinical datasets.
  2. Advancing research on SARS-CoV-2 transmission, variants, methods and analysis tools.
  3. Coordinating a global SARS-CoV-2 genomics training programme (COG-Train).

Data linkage and analysis

By linking and analysing different types of data, it is possible to undertake more in depth research and generate new understanding about the differences in the transmission of SARS-CoV-2 variants and the disease that they cause.

COG-UK collaborated with partners through the UK Health Data Research Alliance and the Outbreak Data Analysis Platform (ODAP) to link viral genome data with other complex datasets. [37] [38]

Through these collaborations, SARS-CoV-2 sequencing data has been linked to a number of different datasets including:

All such linked data are stored securely with controlled access through approved pathways to maintain patient privacy and ensure appropriate usage and attribution. [39]

Research

COG-UK provided seed funding for consortium members to undertake research projects that would generate novel insights relevant to the COVID-19 pandemic, and to prepare for future pandemics. [40]

These projects focussed on:

  1. Monitoring and understanding the emergence of SARS-CoV-2 variants with the potential to transmit more readily and/or circumvent immunity.
  2. Integrating pathogen genome data with diagnostic and rapid genotyping data to strengthen pandemic preparedness.
  3. Developing online resources to improve access to quality control processes for SARS-CoV-2 genome data.
  4. Improving linkage and integration of genomic data with different types of epidemiological and clinical metadata.
  5. Developing metagenomic technologies for the surveillance of known and unknown pathogens with the potential to impact human health.

COG-UK also provided seed funding for consortium members to support early career scientists reinvigorate research projects delayed owing to time spent on the pandemic response. [4]

Training

Together with Wellcome Connecting Science, COG-UK established a free international online learning programme in using genomics to investigate SARS-CoV-2 and other infectious diseases. Known as COG-Train, the programme sought to ‘facilitate an increase global genome sequencing and analysis capacity, reduce sequencing inequality and enhance pathogen surveillance’. Its training courses were built through partnerships with international researchers, public health experts and surveillance networks. Outputs of COG-Train included a series of massive online, open-access courses on all aspects of SARS-CoV-2 sequencing, as well as week-long intensive virtual training courses, short expert workshops and concurrent distributed classrooms. [41]

Funded by the Wellcome Trust and the Foreign, Commonwealth & Development Office, COG-Train delivered free online training to thousands of learners in more than 100 countries worldwide. Its three-week course 'The Power of Genomics to Understand the COVID-19 Pandemic' remains available through the FutureLearn platform. [42] This and all other COG-UK training resources have been preserved via the GitHub repository and remain easily and openly accessible for the long-term.

COG-Train was recognised at the Cambridge Independent Science and Technology Awards 2024, receiving Highly Commended in the ‘Tech For Good’ award category. [43]

Protocol and tool development

Protocols and tools developed by COG-UK consortium members were used globally during the first three years of the COVID-19 pandemic and continue to be of utility today. These include:

By December 2020, the number of sequences uploaded to GISAID by COG-UK was just under 5% of all UK COVID-19 cases, compared to 3.2% for the United States and 60% for Australia. [19] Approximately 60% of these were sequenced at the Wellcome Sanger Institute [18] and the COG-UK consortium was reported to have understood 'the genetic history of more than 150,000 samples of SARS-CoV-2 virus'. [52]

According to the COG-UK website, by December 2021, the UK had sequenced over 1.8 million SARS-CoV-2 genomes. [53]

Events

Seminars and showcases

COG-UK ran a series of events to share the advances and discoveries arising from the work of consortium members and to provide forums for discussion. These included seminars and science showcases, [54] [55] where consortium members have shared their analyses and insights with each other and the public.

In October 2021, the COG-UK Together event saw members from across the consortium join a mixed online/in person event to share their experiences during the first 18 months of the pandemic. [56]

Women in COG

Consortium members also organised and hosted the ‘Women in COG’ interview series, which showcased the lives and work of inspirational women (and male supporters/allies) from the COG-UK network and outside of the consortium. Interviewees included:

This series was also distilled into a book titled 'Snapshots of Women in COG: Scientific Excellence during the COVID-19 pandemic'. [70]

Legacy

Publications

COG-UK members produced more than 100 publications [71] using the data, analysis and tools developed between April 2020 and March 2023. [72]

Rand Europe evaluation

An independent evaluation undertaken by Rand Europe reported that COG-UK made ‘diverse contributions to understanding and responding to the COVID-19 pandemic’ and ‘a significant and valuable contribution to the UK's public health genomics landscape’. [73]

The report identified the key COG-UK achievements as:

  1. Helping to advance scientific knowledge about SARS-CoV-2 and improve genome sequencing and analysis methodologies.
  2. Informing key policy and public health decisions made in response to the COVID-19 pandemic in the UK.
  3. Informing medical innovation efforts, including evaluation of vaccine efficacy against SARS-CoV-2 variants and their susceptibility to therapeutics.
  4. Influencing how decision makers value pathogen genomics in building effective public health systems.
  5. Strengthening the UK pathogen genomics capacity and ability to respond to future infectious disease threats.
  6. Influenced international SARS-CoV-2 sequencing initiatives.

History of COG-UK

The story of the consortium has been captured in 'Cracking Covid: The history of COG-UK', an exhibition curated by historian of medicine Lara Marks which documents the work and achievements of COG-UK based on interviews with more than eighty consortium members. [74] The exhibition is free to access through the 'What is biotechnology' platform.

Selected publications

Related Research Articles

<span class="mw-page-title-main">BGI Group</span> Chinese genome sequencing company

BGI Group, formerly Beijing Genomics Institute, is a Chinese genomics company with headquarters in Yantian, Shenzhen. The company was originally formed in 1999 as a genetics research center to participate in the Human Genome Project. It also sequences the genomes of other animals, plants and microorganisms.

<span class="mw-page-title-main">Wellcome Sanger Institute</span> British genomics research institute

The Wellcome Sanger Institute, previously known as The Sanger Centre and Wellcome Trust Sanger Institute, is a non-profit British genomics and genetics research institute, primarily funded by the Wellcome Trust.

<span class="mw-page-title-main">GISAID</span> Global initiative for sharing virus data

GISAID, the Global Initiative on Sharing All Influenza Data, previously the Global Initiative on Sharing Avian Influenza Data, is a global science initiative established in 2008 to provide access to genomic data of influenza viruses. The database was expanded to include the coronavirus responsible for the COVID-19 pandemic, as well as other pathogens. The database has been described as "the world's largest repository of COVID-19 sequences". GISAID facilitates genomic epidemiology and real-time surveillance to monitor the emergence of new COVID-19 viral strains across the planet.

<span class="mw-page-title-main">Institute of Genomics and Integrative Biology</span> Indian scientific research institute

CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB) is a scientific research institute devoted primarily to biological research. It is a part of Council of Scientific and Industrial Research (CSIR), India.

Dr Vinod Scaria FRSB, FRSPH is an Indian biologist, medical researcher pioneering in Precision Medicine and Clinical Genomics in India. He is best known for sequencing the first Indian genome. He was also instrumental in the sequencing of The first Sri Lankan Genome, analysis of the first Malaysian Genome sequencing and analysis of the Wild-type strain of Zebrafish and the IndiGen programme on Genomics for Public Health in India.

The 100,000 Genomes Project is a now-completed UK Government project managed by Genomics England that is sequencing whole genomes from National Health Service patients. The project is focusing on rare diseases, some common types of cancer, and infectious diseases. Participants give consent for their genome data to be linked to information about their medical condition and health records. The medical and genomic data is shared with researchers to improve knowledge of the causes, treatment, and care of diseases. The project has received over £300 million from public and private investment.

Mark J. Pallen is a research leader at the Quadram Institute and Professor of Microbial Genomics at the University of East Anglia. In recent years, he has been at the forefront of efforts to apply next-generation sequencing to problems in microbiology and ancient DNA research.

Sharon Jayne Peacock is a British microbiologist who is Professor of Public Health and Microbiology in the Department of Medicine at the University of Cambridge, and Master of Churchill College, Cambridge.

<span class="mw-page-title-main">Tanja Stadler</span> German mathematician and professor of computational evolution

Tanja Stadler is a mathematician and professor of computational evolution at the Swiss Federal Institute of Technology. She’s the current president of the Swiss Scientific Advisory Panel COVID-19 and Vize-Chair of the Department of Biosystems Science and Engineering at ETH Zürich.

<span class="mw-page-title-main">SARS-CoV-2</span> Virus that causes COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a strain of coronavirus that causes COVID-19, the respiratory illness responsible for the COVID-19 pandemic. The virus previously had the provisional name 2019 novel coronavirus (2019-nCoV), and has also been called human coronavirus 2019. First identified in the city of Wuhan, Hubei, China, the World Health Organization designated the outbreak a public health emergency of international concern from January 30, 2020, to May 5, 2023. SARS‑CoV‑2 is a positive-sense single-stranded RNA virus that is contagious in humans.

<span class="mw-page-title-main">SARS-CoV-2 Alpha variant</span> Variant of SARS-CoV-2, the virus that causes COVID-19

The Alpha variant (B.1.1.7) was a SARS-CoV-2 variant of concern. It was estimated to be 40–80% more transmissible than the wild-type SARS-CoV-2. Scientists more widely took note of this variant in early December 2020, when a phylogenetic tree showing viral sequences from Kent, United Kingdom looked unusual.

<span class="mw-page-title-main">SARS-CoV-2 Beta variant</span> Variant of the SARS-CoV-2 virus

The Beta variant, (B.1.351), was a variant of SARS-CoV-2, the virus that causes COVID-19. One of several SARS-CoV-2 variants initially believed to be of particular importance, it was first detected in the Nelson Mandela Bay metropolitan area of the Eastern Cape province of South Africa in October 2020, which was reported by the country's health department on 18 December 2020. Phylogeographic analysis suggests this variant emerged in the Nelson Mandela Bay area in July or August 2020.

<span class="mw-page-title-main">Variants of SARS-CoV-2</span> Notable variants of SARS-CoV-2

Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are viruses that, while similar to the original, have genetic changes that are of enough significance to lead virologists to label them separately. SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Some have been stated, to be of particular importance due to their potential for increased transmissibility, increased virulence, or reduced effectiveness of vaccines against them. These variants contribute to the continuation of the COVID-19 pandemic.

<span class="mw-page-title-main">SARS-CoV-2 Gamma variant</span> Variant of the virus SARS-CoV-2

The Gamma variant (P.1) was one of the variants of SARS-CoV-2, the virus that causes COVID-19. This variant of SARS-CoV-2 has been named lineage P.1 and has 17 amino acid substitutions, ten of which in its spike protein, including these three designated to be of particular concern: N501Y, E484K and K417T. It was first detected by the National Institute of Infectious Diseases (NIID) of Japan, on 6 January 2021 in four people who had arrived in Tokyo having visited Amazonas, Brazil, four days earlier. It was subsequently declared to be in circulation in Brazil. Under the simplified naming scheme proposed by the World Health Organization, P.1 was labeled Gamma variant, and was considered a variant of concern until March 2022, when it was largely displaced by the delta and omicron variants.

<span class="mw-page-title-main">Phylogenetic Assignment of Named Global Outbreak Lineages</span> SARS-CoV-2 lineage nomenclature

The Phylogenetic Assignment of Named Global Outbreak Lineages (PANGOLIN) is a software tool developed by Dr. Áine O'Toole and members of the Andrew Rambaut laboratory, with an associated web application developed by the Centre for Genomic Pathogen Surveillance in South Cambridgeshire. Its purpose is to implement a dynamic nomenclature to classify genetic lineages for SARS-CoV-2, the virus that causes COVID-19. A user with a full genome sequence of a sample of SARS-CoV-2 can use the tool to submit that sequence, which is then compared with other genome sequences, and assigned the most likely lineage. Single or multiple runs are possible, and the tool can return further information regarding the known history of the assigned lineage. Additionally, it interfaces with Microreact, to show a time sequence of the location of reports of sequenced samples of the same lineage. This latter feature draws on publicly available genomes obtained from the COVID-19 Genomics UK Consortium and from those submitted to GISAID. It is named after the pangolin.

The Centre for Genomic Pathogen Surveillance is a computational genomics research institute in Oxfordshire.

Jemma Louise Geoghegan is a Scottish-born evolutionary virologist, based at the University of Otago, New Zealand, who specialises in researching emerging infectious diseases and the use of metagenomics to trace the evolution of viruses. As a leader in several government-funded research projects, Geoghegan became the public face of genomic sequencing during New Zealand's response to COVID-19. Her research has contributed to the discussion about the likely cause of COVID-19 and the challenges around predicting pandemics. She was a recipient of the Young Tall Poppy Award in 2017, a Rutherford Discovery Fellowship in 2020, and the 2021 Prime Minister's Emerging Scientist Prize.

<span class="mw-page-title-main">Christian Happi</span> Professor of Molecular Biology and Genomics

Christian Happi is a Professor of Molecular Biology and Genomics in the Department of Biological Sciences and the Director of the African Centre of Excellence for Genomics of Infectious Diseases, both at Redeemer’s University. He is known for leading the team of scientists that used genomic sequencing to identify a single point of infection from an animal reservoir to a human in the Ebola outbreak in West Africa. His research focus is on infectious diseases, including malaria, Lassa fever, Ebola virus disease, HIV, and SARS-CoV-2.

The COVID Moonshot is a collaborative open-science project started in March 2020 with the goal of developing an un-patented oral antiviral drug to treat SARS-CoV-2, the virus causing COVID-19. COVID Moonshot researchers are targeting the proteins needed to form functioning new viral proteins. They are particularly interested in proteases such as 3C-like protease (Mpro), a coronavirus nonstructural protein that mediates the breaking and replication of proteins.

Tulio de Oliveira is a Brazilian, Portuguese, and South African permanent resident professor of bioinformatics at the University of KwaZulu-Natal and Stellenbosch University, South Africa, and associate professor of global health at the University of Washington. He has studied outbreaks of chikungunya, dengue, hepatitis B and C, HIV, SARS-CoV-2, yellow fever and Zika. During the COVID-19 pandemic he led the team that confirmed the discovery of the Beta variant of the COVID-19 virus in 2020 and the Omicron variant in 2021.

References

  1. 1 2 3 "UK launches whole genome sequence alliance to map spread of coronavirus". COG-UK Consortium. 23 March 2020. Archived from the original on 25 September 2020. Retrieved 23 December 2020.
  2. ↑ Peacock, Sharon (17 December 2020). "A short history of the COVID-19 Genomics UK (COG-UK) Consortium". COG-UK Consortium. Archived from the original on 17 December 2020. Retrieved 19 January 2021.
  3. ↑ Gallagher, James (23 March 2020). "Coronavirus to be tracked using its genetic code". www.bbc.co.uk. Retrieved 27 January 2021. The project - called the Covid-19 Genomics UK Consortium - is a collaboration between the NHS, public health agencies and the Wellcome Sanger Institute universities. Business Secretary Alok Sharma said: "This new consortium will bring together the UK's brightest and best scientists to build our understanding of this pandemic, tackle the disease and ultimately, save lives."
  4. 1 2 3 "UK Government Web Archive". webarchive.nationalarchives.gov.uk. Retrieved 23 January 2024.
  5. ↑ Dec 2020, COG-UK 14 (14 December 2020). "Update on new SARS-CoV-2 variant and how COG-UK tracks emerging mutations - COG-UK Consortium". www.cogconsortium.uk. Retrieved 19 January 2021.{{cite web}}: CS1 maint: numeric names: authors list (link)
  6. ↑ Wise, Jacqui (16 December 2020). "Covid-19: New coronavirus variant is identified in UK". BMJ. 371: m4857. doi: 10.1136/bmj.m4857 . ISSN   1756-1833. PMID   33328153.
  7. ↑ "How SARS-CoV-2 sequencing is becoming a national service". COG-UK consortium. 23 July 2021. Archived from the original on 25 July 2021.
  8. 1 2 "What next for COG-UK?". 20 April 2021. Archived from the original on 20 April 2021.
  9. ↑ Nov 2020, COG-UK 16 (16 November 2020). "£12.2 million boost for SARS-CoV-2 real-time genomic surveillance - COG-UK Consortium". www.cogconsortium.uk. Retrieved 19 January 2021.{{cite web}}: CS1 maint: numeric names: authors list (link)
  10. ↑ "COG-Train Programme". Wellcome Connecting Science Courses and Conferences. Retrieved 9 July 2024.
  11. ↑ "COG-UK and Wellcome Connecting Science receive funding from Wellcome and the Foreign, Commonwealth & Development Office for a global training programme in SARS-CoV-2 genomics". Wellcome Connecting Science Courses and Conferences. Retrieved 23 January 2024.
  12. ↑ "COVID-19 Genomics UK (COG-UK) Consortium". www.sanger.ac.uk. Retrieved 23 January 2024.
  13. ↑ "Consortium Partners". COG-UK Consortium. Retrieved 22 December 2020.
  14. ↑ "How the Covid-19 Genomics UK Consortium sequenced Sars-Cov-2 | Computer Weekly". ComputerWeekly.com. Retrieved 23 January 2024.
  15. ↑ Connor, Thomas R.; Loman, Nicholas J.; Thompson, Simon; Smith, Andy; Southgate, Joel; Poplawski, Radoslaw; Bull, Matthew J.; Richardson, Emily; Ismail, Matthew; Thompson, Simon Elwood-; Kitchen, Christine; Guest, Martyn; Bakke, Marius; Sheppard, Samuel K.; Pallen, Mark J. (20 September 2016). "CLIMB (the Cloud Infrastructure for Microbial Bioinformatics): an online resource for the medical microbiology community". Microbial Genomics. 2 (9): e000086. doi: 10.1099/mgen.0.000086 . ISSN   2057-5858. PMC   5537631 . PMID   28785418.
  16. ↑ "CLIMB | Cloud Infrastructure for Microbial Bioinformatics" . Retrieved 23 January 2024.
  17. 1 2 Nicholls, Samuel M.; Poplawski, Radoslaw; Bull, Matthew J.; Underwood, Anthony; Chapman, Michael; Abu-Dahab, Khalil; Taylor, Ben; Colquhoun, Rachel M.; Rowe, Will P. M.; Jackson, Ben; Hill, Verity; O’Toole, Áine; Rey, Sara; Southgate, Joel; Amato, Roberto (December 2021). "CLIMB-COVID: continuous integration supporting decentralised sequencing for SARS-CoV-2 genomic surveillance". Genome Biology. 22 (1): 196. doi: 10.1186/s13059-021-02395-y . ISSN   1474-760X. PMC   8247108 . PMID   34210356.
  18. 1 2 "How Britain has done so much sequencing of the coronavirus genome" . www.economist.com. 16 January 2021. Retrieved 28 February 2021.
  19. 1 2 3 Cyranoski, David (15 January 2021). "Alarming COVID variants show vital role of genomic surveillance". Nature. 589 (7842): 337–338. Bibcode:2021Natur.589..337C. doi:10.1038/d41586-021-00065-4. PMID   33452508. S2CID   231621736.
  20. ↑ Peacock, Sharon (21 March 2023). "COG-UK's final flight". GOV.UK. COG-UK. Archived from the original on 22 May 2023 – via The National Archives.
  21. ↑ "Key Contributors". GOV.UK. COG-UK. Archived from the original on 7 May 2023 – via The National Archives.
  22. ↑ "Management Team". GOV.UK. COG-UK. Archived from the original on 7 May 2023 – via The National Archives.
  23. ↑ Lo, Stephanie W.; Jamrozy, Dorota (20 July 2020). "Genomics and epidemiological surveillance". Nature Reviews Microbiology. 18 (9): 478. doi:10.1038/s41579-020-0421-0. ISSN   1740-1534. PMC   7371787 . PMID   32690878.
  24. ↑ Davies, Nicholas G.; Abbott, Sam; Barnard, Rosanna C.; Jarvis, Christopher I.; Kucharski, Adam J.; Munday, James D.; Pearson, Carl A. B.; Russell, Timothy W.; Tully, Damien C.; Washburne, Alex D.; Wenseleers, Tom (9 April 2021). "Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England". Science. 372 (6538): eabg3055. doi:10.1126/science.abg3055. ISSN   0036-8075. PMC   8128288 . PMID   33658326.
  25. ↑ Stirrup, Oliver; Blackstone, James; Mapp, Fiona; MacNeil, Alyson; Panca, Monica; Holmes, Alison; Machin, Nicholas; Shin, Gee Yen; Mahungu, Tabitha; Saeed, Kordo; Saluja, Tranprit; Taha, Yusri; Mahida, Nikunj; Pope, Cassie; Chawla, Anu (13 September 2022). "Effectiveness of rapid SARS-CoV-2 genome sequencing in supporting infection control for hospital-onset COVID-19 infection: Multicentre, prospective study". eLife. 11. doi: 10.7554/eLife.78427 . ISSN   2050-084X. PMC   9596156 . PMID   36098502.
  26. ↑ Colton, H.; Parker, M.D.; Stirrup, O.; Blackstone, J.; Loose, M.; McClure, C.P.; Roy, S.; Williams, C.; McLeod, J.; Smith, D.; Taha, Y.; Zhang, P.; Hsu, S.N.; Kele, B.; Harris, K. (January 2023). "Factors affecting turnaround time of SARS-CoV-2 sequencing for inpatient infection prevention and control decision making: analysis of data from the COG-UK HOCI study". Journal of Hospital Infection. 131: 34–42. doi:10.1016/j.jhin.2022.09.022. PMC   9550290 . PMID   36228768.
  27. ↑ Panca, M.; Blackstone, J.; Stirrup, O.; Cutino-Moguel, M.-T.; Thomson, E.; Peters, C.; Snell, L.B.; Nebbia, G.; Holmes, A.; Chawla, A.; Machin, N.; Taha, Y.; Mahungu, T.; Saluja, T.; de Silva, T.I. (September 2023). "Evaluating the cost implications of integrating SARS-CoV-2 genome sequencing for infection prevention and control investigation of nosocomial transmission within hospitals". Journal of Hospital Infection. 139: 23–32. doi:10.1016/j.jhin.2023.06.005. PMC   10257337 . PMID   37308063.
  28. ↑ "COVID-19 Infection Survey". Archived from the original on 1 March 2021.
  29. ↑ Lythgoe, Katrina A.; Golubchik, Tanya; Hall, Matthew; House, Thomas; Cahuantzi, Roberto; MacIntyre-Cockett, George; Fryer, Helen; Thomson, Laura; Nurtay, Anel; Ghafani, Mahan; Buck, David; Green, Angie; Trebes, Amy; Piazza, Paolo; Lonie, Lorne J. (25 October 2023). "Lineage replacement and evolution captured by 3 years of the United Kingdom Coronavirus (COVID-19) Infection Survey". Proceedings of the Royal Society B: Biological Sciences. 290 (2009). doi:10.1098/rspb.2023.1284. ISSN   0962-8452. PMC   10581763 . PMID   37848057.
  30. ↑ "Real-time Assessment of Community Transmission (REACT) Study". Archived from the original on 6 July 2020.
  31. ↑ Eales, Oliver; Haw, David; Wang, Haowei; Atchison, Christina; Ashby, Deborah; Cooke, Graham S.; Barclay, Wendy; Ward, Helen; Darzi, Ara; Donnelly, Christl A.; Chadeau-Hyam, Marc; Elliott, Paul; Riley, Steven (25 May 2023). Dushoff, Jonathan (ed.). "Dynamics of SARS-CoV-2 infection hospitalisation and infection fatality ratios over 23 months in England". PLOS Biology. 21 (5): e3002118. doi: 10.1371/journal.pbio.3002118 . ISSN   1545-7885. PMC   10212114 . PMID   37228015.
  32. ↑ "Vivaldi study: results". Archived from the original on 28 May 2021.
  33. ↑ UCL (29 July 2020). "VIVALDI". UCL Institute of Health Informatics. Retrieved 23 January 2024.
  34. ↑ Emary, Katherine R. W.; Golubchik, Tanya; Aley, Parvinder K.; Ariani, Cristina V.; Angus, Brian; Bibi, Sagida; Blane, Beth; Bonsall, David; Cicconi, Paola; Charlton, Sue; Clutterbuck, Elizabeth A. (10 April 2021). "Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial". The Lancet. 397 (10282): 1351–1362. doi:10.1016/S0140-6736(21)00628-0. ISSN   0140-6736. PMC   8009612 . PMID   33798499.
  35. ↑ "PREVENT-19: A COVID-19 vaccine candidate clinical trial". Archived from the original on 28 December 2020.
  36. ↑ Boshier, Florencia A. T.; Pang, Juanita; Penner, Justin; Parker, Matthew; Alders, Nele; Bamford, Alasdair; Grandjean, Louis; Grunewald, Stephanie; Hatcher, James; Best, Timothy; Dalton, Caroline (2022). "Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients". Journal of Medical Virology. 94 (1): 161–172. doi:10.1002/jmv.27285. ISSN   1096-9071. PMC   8426849 . PMID   34415583.
  37. ↑ "Why COG-UK is joining the UK Health Data Research Alliance". HDR UK. Retrieved 23 January 2024.
  38. ↑ "Outbreak Data Analysis Platform". ODAP - Outbreak Data Analysis Platform. Retrieved 23 January 2024.
  39. ↑ "UK Government Web Archive". webarchive.nationalarchives.gov.uk. Retrieved 23 January 2024.
  40. ↑ "WhatisBiotechnology • The sciences, places and people that have created biotechnology". WhatisBiotechnology.org. Retrieved 23 January 2024.
  41. ↑ "UK Government Web Archive". webarchive.nationalarchives.gov.uk. Retrieved 23 January 2024.
  42. ↑ "Genomics and COVID-19 – Online Course". FutureLearn. Retrieved 9 July 2024.
  43. ↑ "Winners of the 2024 Cambridge Independent Science and Technology Awards revealed". Cambridge Independent. 16 May 2024. Retrieved 9 July 2024.
  44. ↑ Quick, Josh (22 January 2020). "nCoV-2019 sequencing protocol".{{cite journal}}: Cite journal requires |journal= (help)
  45. ↑ Tyson, John R; James, Phillip; Stoddart, David; Sparks, Natalie; Wickenhagen, Arthur; Hall, Grant; Choi, Ji Hyun; Lapointe, Hope; Kamelian, Kimia (4 September 2020). Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore (Report). Genomics. doi:10.1101/2020.09.04.283077. PMC   7480024 . PMID   32908977.
  46. 1 2 O’Toole, Áine; Scher, Emily; Underwood, Anthony; Jackson, Ben; Hill, Verity; McCrone, John T; Colquhoun, Rachel; Ruis, Chris; Abu-Dahab, Khalil; Taylor, Ben; Yeats, Corin; du Plessis, Louis; Maloney, Daniel; Medd, Nathan; Attwood, Stephen W (16 December 2021). "Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool". Virus Evolution. 7 (2): veab064. doi:10.1093/ve/veab064. ISSN   2057-1577. PMC   8344591 . PMID   34527285.
  47. ↑ "COVID-19 Genomics UK (COG-UK) Consortium Report #10 -11th August 2020 (see section 'Summary of major tools and pipelines developed by COG-UK')" (PDF). www.cogconsortium.uk. 11 August 2020. Retrieved 23 January 2021.
  48. ↑ O'Toole, Áine; Hill, Verity; Pybus, Oliver G.; Watts, Alexander; Bogoch, Issac I.; Khan, Kamran; Messina, Jane P.; The COVID-19 Genomics UK (COG-UK) consortium; Network for Genomic Surveillance in South Africa (NGS-SA); Brazil-UK CADDE Genomic Network; Tegally, Houriiyah; Lessells, Richard R.; Giandhari, Jennifer; Pillay, Sureshnee; Tumedi, Kefentse Arnold (17 September 2021). "Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with grinch". Wellcome Open Research. 6: 121. doi: 10.12688/wellcomeopenres.16661.2 . ISSN   2398-502X. PMC   8176267 . PMID   34095513.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  49. ↑ "Cov-Lineages". cov-lineages.org. Retrieved 23 January 2024.
  50. ↑ "COG-UK/Mutation Explorer". sars2.cvr.gla.ac.uk. Retrieved 23 January 2024.
  51. ↑ "CoV-GLUE: SARS-CoV-2 mutations". cov-glue.cvr.gla.ac.uk. Retrieved 23 January 2024.
  52. ↑ Schraer, Rachel (22 December 2020). "Covid: New variant found 'due to hard work of UK scientists'". www.bbc.co.uk. Retrieved 23 January 2021.
  53. ↑ "COVID-19 Genomics Consortium". 31 December 2021. Archived from the original on 28 April 2020.
  54. ↑ COG-UK Showcase Event December 2020 , retrieved 23 January 2024
  55. ↑ COG-UK Science Showcase March 2021 , retrieved 23 January 2024
  56. ↑ "COG-UK Together - YouTube". www.youtube.com. Retrieved 23 January 2024.
  57. ↑ COG-UK's first 'Women in COG' event, featuring Dr Charlotte Summers , retrieved 23 January 2024
  58. ↑ COG-UK's 'Women in COG' event with Professor Judy Breuer of UCL , retrieved 23 January 2024
  59. ↑ COG-UK's 'Women in COG' event with Angela Douglas MBE , retrieved 23 January 2024
  60. ↑ COG-UK's 'Women in COG' event with Dr Magdalena Skipper, Editor in Chief of Nature , retrieved 23 January 2024
  61. ↑ COG-UK's 'Women in COG' event with Dr June Raine, Chief Executive of MHRA , retrieved 23 January 2024
  62. ↑ COG-UK's 'Women in COG' event with Sir Jeremy Farrar in conversation with Professor Sharon Peacock , retrieved 23 January 2024
  63. ↑ COG-UK's 'Women in COG' event with Dr Maria Van Kerkhove of the World Health Organization (WHO) , retrieved 23 January 2024
  64. ↑ COG-UK's 'Women in COG' event with Colby Benari, CEO of In2Science , retrieved 23 January 2024
  65. ↑ COG-UK's 'Women in COG' event with Dr Senjuti Saha, Director at the Child Health Research Foundation , retrieved 23 January 2024
  66. ↑ COG-UK's 'Women in COG' event with Emma Thomson, OBE, Professor in Infectious Diseases at the MRC , retrieved 23 January 2024
  67. ↑ COG-UK's 'Women in COG' event with Dame Kate Bingham, former Chair of the UK Vaccine Taskforce , retrieved 23 January 2024
  68. ↑ COG-UK's 'Women in COG' event with Professor Mariana Viegas, Coordinator of the PAIS project , retrieved 23 January 2024
  69. ↑ COG-UK's 'Women in COG' event with Dr Sam Barrell, Deputy Chief Executive, Francis Crick Institute. , retrieved 23 January 2024
  70. ↑ Snapshots of Women in COG: Scientific excellence during the COVID-19 pandemic. 13 January 2023 – via Fliphtml5.com.
  71. ↑ "COG-UK Publications". GOV.UK. 31 March 2023. Archived from the original on 7 May 2023 – via The National Archives.
  72. ↑ "COVID-19 Genomics UK (COG-UK) Consortium[Corporate Author] - Search Results - PubMed". PubMed. Retrieved 23 January 2024.
  73. ↑ Marjanovic, Sonja; Romanelli, Robert J.; Ali, Gemma-Claire; Leach, Brandi; Bonsu, Margaretha; Rodriguez-Rincon, Daniela; Ling, Tom (31 August 2022). "COVID-19 Genomics UK (COG-UK) Consortium: Final Report". Rand Health Quarterly. 9 (4): 24. ISSN   2162-8254. PMC   9519096 . PMID   36238008.
  74. ↑ Marks, Lara (April 2023). "Cracking Covid: The history of COG-UK". What Is Biotechnology. Retrieved 9 July 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.